Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin: The Updated College of American Pathologists Protocol
The updated CAP Gynecologic Biomarker Protocol provides improved structure and clarity in the reporting of prognostic and/or therapeutic biomarkers and comprehensive explanatory notes that aid in understanding the rationale for testing, interpretive guidance, and common testing pitfalls, based on the current standard of care.
Authors
- Anthony N. Karnezis (ORCID: https://orcid.org/0000-0003-2924-1126)
- Gulisa Turashvili (ORCID: https://orcid.org/0000-0001-6125-5865)
- Anne M. Mills (ORCID: https://orcid.org/0000-0002-2686-4857)
- Kristin K. Deeb (ORCID: https://orcid.org/0000-0002-2710-5406)
- Krisztina Hanley (ORCID: https://orcid.org/0000-0002-7841-4700)
- Colleen Hebert
- Keren I. Hulkower
- Lara R. Harik (ORCID: https://orcid.org/0000-0001-7091-4076)
- Raji Ganesan (ORCID: https://orcid.org/0000-0002-6553-2855)
- Barbara A. Crothers (ORCID: https://orcid.org/0000-0003-3191-9514)
- Natália Buza (ORCID: https://orcid.org/0000-0002-0008-334X)
- Giovanna A. Giannico (ORCID: https://orcid.org/0000-0002-0326-3207)
Institutions
- Indiana University Health (US)
- College of American Pathologists (US)
- University of Virginia Health System (US)
- Emory University Hospital (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Birmingham Women's Hospital (GB)
- James H. Quillen VA Medical Center (US)
- Yale New Haven Health System (US)
- Indiana University – Purdue University Indianapolis (US)
- University of California, Davis (US)
Publication Details
- Journal
- Archives of Pathology & Laboratory Medicine
- Published
- 2025-09-16
- DOI
- https://doi.org/10.5858/arpa.2025-0157-cp
- Citations
- 3
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.09
Funders
- GlaxoSmithKline
- Daiichi Sankyo Europe